Profund Advisors LLC purchased a new stake in Kodiak Sciences Inc. (NASDAQ:KOD – Free Report) during the fourth quarter, HoldingsChannel.com reports. The firm purchased 22,092 shares of the company’s stock, valued at approximately $618,000.
Other institutional investors have also recently modified their holdings of the company. GF Fund Management CO. LTD. purchased a new stake in shares of Kodiak Sciences in the fourth quarter valued at approximately $29,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Kodiak Sciences in the fourth quarter valued at approximately $72,000. Strs Ohio purchased a new stake in shares of Kodiak Sciences in the fourth quarter valued at approximately $87,000. BNP Paribas Financial Markets boosted its stake in shares of Kodiak Sciences by 89.4% in the third quarter. BNP Paribas Financial Markets now owns 6,373 shares of the company’s stock valued at $104,000 after buying an additional 3,009 shares in the last quarter. Finally, Diversified Trust Co. purchased a new stake in shares of Kodiak Sciences in the fourth quarter valued at approximately $219,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.
Kodiak Sciences Price Performance
Shares of NASDAQ:KOD opened at $36.23 on Friday. The business’s 50 day simple moving average is $37.49 and its 200-day simple moving average is $29.01. The firm has a market capitalization of $2.27 billion, a price-to-earnings ratio of -8.69 and a beta of 2.32. Kodiak Sciences Inc. has a 12 month low of $3.26 and a 12 month high of $47.84.
Wall Street Analyst Weigh In
A number of equities research analysts have recently issued reports on KOD shares. Chardan Capital upgraded shares of Kodiak Sciences from a “neutral” rating to a “buy” rating and lifted their price target for the company from $14.00 to $61.00 in a research report on Monday, May 11th. UBS Group boosted their price target on Kodiak Sciences from $50.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, March 27th. Wall Street Zen raised Kodiak Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, HC Wainwright reissued a “buy” rating and set a $58.00 price target (up from $38.00) on shares of Kodiak Sciences in a research note on Friday, March 27th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Kodiak Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $42.14.
View Our Latest Stock Report on KOD
Kodiak Sciences Company Profile
Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.
The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.
Featured Articles
- Five stocks we like better than Kodiak Sciences
- SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
- CAVA Group’s Stock Looks Delicious After Strong Earnings
- Lowe’s Finds Support at $215 After Q1 Earnings Sell-Off
- Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook
Want to see what other hedge funds are holding KOD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kodiak Sciences Inc. (NASDAQ:KOD – Free Report).
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
